vimarsana.com
Home
Live Updates
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session : vimarsana.com
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
WALTHAM - Syndax Pharmaceuticals , a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of positive data from the pivotal...
Related Keywords
Seattle
,
Washington
,
United States
,
American
,
Neil Gallagher
,
Sharon Klahre
,
Syndax Pharmaceuticals
,
Time Oncology Review Program
,
Exchange Commission
,
American Society Of Hematology Annual Meeting
,
American Society Of Pediatric Hematology Oncology
,
European Commission
,
Head Of Research
,
Plenary Session
,
Pivotal Phase
,
Acute Leukemia
,
Pediatric Experience
,
Hematology Annual
,
Orphan Drug Designation
,
Fast Track
,
Breakthrough Therapy Designation
,
New Drug Application
,
Priority Review
,
Prescription Drug User Fee Act
,
Real Time Oncology Review
,
Rearranged Acute
,
Private Securities Litigation Reform Act
,
Risk Factor
,
News Publishing
,
Markets
,
vimarsana.com © 2020. All Rights Reserved.